Background. Prophylactic therapy with silymarin to prevent the development of antituberculosis drug-induced liver injury (anti-TB DILI) has been under debate. We aimed to evaluate the effect of silymarin in the prevention of anti-TB DILI. Methods. We searched MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to 30th November 2018. Randomized controlled trials (RCTs) that compared silymarin and placebo to prevent anti-TB DILI were included. All statistical analyses were conducted using STATA 12.0 software. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) were used to evaluate the effect of silymarin. The quality of included studies was assessed according to Cochrane handbook. Funnel plots and Egger’s tests were carried out to evaluate publication bias. Sensitivity analysis was conducted to assess the influence of each study. Results. A total of 1198 patients from five RCTs (585 with silymarin and 613 with placebo groups) were included. Overall, silymarin significantly reduced the occurrence of anti-TB DILI at week 4 [RR: 0.33, 95% CI (0.15, 0.75)]. In addition, silymarin exerted protective effect on liver function in patients undergoing anti-TB drugs [SMD = − 0.15, 95% CI (−0.24, −0.07), P < 0.001 (ALT); SMD =−0.14, 95% CI (−0.23, −0.06), P = 0.001(AST); SMD =−0.12, 95% CI (−0.20, −0.03), P = 0.008 (ALP)]. Silymarin led to similar AEs in placebo groups [OR: 1.09, 95% CI (0.86, 1.39), P = 0.47]. Conclusion. Prophylactic therapy of silymarin is contributed to a noticeably reduced risk of development of anti-TB DILI four weeks after the initiation. In addition, silymarin significantly improved the liver function in patients who are receiving anti-TB drugs.
National Natural Science Foundation of China81803608Jilin UniversityJDYY820170261. Introduction
Tuberculosis (TB) is a major worldwide health threat and is one of the top 10 causes of death. In 2016, the World Health Organization (WHO) estimated that there were 10.4 million incident TB cases and 1.7 million deaths [1]. The standard combined treatment regimen of anti-TB drugs consists of isoniazid (INH), rifampicin (RIF), pyrazinamide (PZA), and ethambutol (EMB) [2].
Hepatotoxicity, one of the common adverse reactions of anti-TB drugs, varies from asymptomatic elevation of liver enzymes to fulminant hepatic failure. Anti-TB drug-induced liver injury (anti-TB DILI) leads to increased morbidity and mortality. Therefore, it may result in treatment withdrawal, drug interruption and substitution, dosage regimen adjustment, nonadherence, and drug resistance [3, 4]. The overall incidence of anti-TB DILI has been reported to be from 5% to 33%, depending on the definition of DILI and the population investigated [5].
The mechanism of anti-TB DILI remains unclear. INH causes DILI through diverse mechanisms, i.e., by the pathways of toxic metabolites, escalating oxidative stress, generation of reactive oxygen species (ROS), and lipid peroxidation [6]. RIF, an inducer of drug metabolic enzymes, triggers unconjugated hyperbilirubinemia [7]. Previous studies have reported that certain herbal drugs, phytochemicals, and food supplements can prevent and reduce the hepatotoxicity of anti-TB drugs [7].
Silymarin, a traditional herbal medicine extracted from milk thistle (Silybum marianum L. Gaertn) fruits, has been used as a remedy for hepatoprotection [8]. Silymarin is the collective name of flavonolignans comprised of silybin or silibinin, isosilybin, silydianin, and silychristin [8–10]. Silymarin manifests hepatoprotection by scavenging free radicals, raising the glutathione content, inhibiting lipid peroxidation, and restoring the function of enzymes, thereby generating membrane stabilization and preventing toxic metabolic liver injury [11–14].
To date, silymarin has demonstrated significant hepatoprotective effects on anti-TB DILI in animal and vitro experiments [14–16]. However, the effectiveness of silymarin is under debate [17, 18]. Some clinical studies have shown that silymarin possesses positive hepatoprotective effects [19]. In contract, other studies have observed no or limited preventive effect of silymarin [3, 20, 21]. Therefore, we performed this meta-analysis to evaluate the effect of silymarin in the prevention of anti-TB DILI. We hypothesized that use of silymarin would prevent the occurrence of anti-TB DILI in patients with TB receiving anti-TB treatment.
2. Methods
We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines during the preparation of this meta-analysis (Supplementary Table 1) [22]. All steps were carried out according to the Cochrane Handbook for Systematic Reviews of Interventions [23]. The present meta-analysis was not prospectively registered.
2.1. Search Strategy
To identify relevant randomized trials, we searched the literature through MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to 30th November 2018 with the following search strategies: ( “silymarin” or “silibinin” or “silybum” or “silybin” or “silydianin” or “silychristin” or “milk thistle”) and (“tuberculosis” or “tubercul∗” or “antitubercul∗” or “tb”). The search was restricted to English language articles. To identify relevant unpublised studies, we searched “ISRCTN Register” and “ClinicalTrials.gov” with the same search strategies up to 30th November 2018. In addition, we searched all references in the relevant articles, abstracts, presentations or posters presented in scientific conferences, and previously published reviews for additional eligible studies.
2.2. Inclusion and Exclusion Criteria
Two reviewers (Qu and Zhang) independently searched for and examined the relevant studies, and discrepancies were resolved by discussion with a third author (Song). Individual studies of the RCTs on the preventive effect of silymarin on anti-TB drugs induced hepatotoxicity were included for analysis. We excluded the following articles: experimental trials researched in animals, articles focusing on pharmacokinetic or pharmacodynamic variables, and trials focusing on the in vitro activity of silymarin.
2.3. Data Extraction
The following data were extracted from each study: year of publication, type of trial design, number of patients, patient characteristics, treatment protocol, outcome measures, and adverse effects. Two reviewers (Qu and Zhang) independently extracted the relevant data. Disagreements were resolved by discussion with a third author (Song).
2.4. Quality Assessment
The methodological quality of the RCTs was evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [23]. The assessment included the following items: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias. Two reviewers (Qu and Zhang) independently evaluated the quality by classifying as “high”, “low”, or “unclear” risk of bias, and disagreements were resolved by discussion with a third author (Song).
2.5. Outcome Measures
Outcomes were measured for the following: (1) the primary efficacy outcome was the occurrence of anti-TB DILI, which was defined by serum AST or ALT > 2 × upper normal limit (UNL); (2) the key secondary efficacy outcomes were changes in the liver enzymes, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL); (3) the safety outcome was adverse events.
2.6. Statistical Analysis
The meta-analysis was performed using STATA 12.0 (Stata Corporation, College Station, TX, USA). Effect size was calculated as follows: measure at the end of follow-up – measure at baseline. Standard deviations (SDs) of the mean difference were calculated using the following formula: SD = square root [(SDbaseline)2 + SDfollow-up)2 – 2R × SDbaseline × SDfollow-up], assuming a correlation coefficient (R) = 0.5. Mean and SD values were estimated using the methods described by Wan et al. [24], provided the outcome measures were reported in median and interquartile range. We assessed heterogeneity with Q statistics generated from the χ2 test and inconsistency using the I2 measure. Significant heterogeneity was judged with P-values less than 0.10 or I2 more than 50%. We chose to adopt a Mantel-Haenszel fixed-effect model (FEM) for pooling the risk ratio (RR) or standardized mean difference (SMD) and 95% confidence interval (CI) for outcomes when heterogeneity was not significant. We chose a DerSimonian and Laird random-effects model (REM) when heterogeneity was obvious. Subgroup analyses were conducted according to inconsistent follow-up period and different study design. Sensitivity analysis was performed to test the influence of a single study on the overall effect size by the leave-one-out method. Possible publication bias in the meta-analysis was explored using Egger’s test.
3. Results3.1. Study Selection Outcomes
The trial flow chart in Figure 1 shows the details of the study selection process. A total of 34 studies were identified, 17 of which were excluded based on title and abstracts, and 10 full-texts were retrieved. However, one [3] was not an RCT, seven were duplicate publications of the same study, nine [15, 25–32] were animal studies, four [14, 16, 33, 34] were in vitro research studies, three [35–37] were irrelevant to this study, one [38] was a conference summary without available results, one [39] was a clinical trial with unknown recruitment status, one [40] study’s data could not be used, and one [41] was a review. Therefore, finally five RCTs [19–21, 42, 43] were included in the meta-analysis.
Flow diagram of literature screening and selection process.
3.2. Study Characteristics and Quality Assessment
A total of 585 and 613 patients were randomly treated with silymarin and placebo, respectively. Table 1 shows the main characteristics of the studies included in the meta-analysis.
Baseline characteristics of the trials included in the meta-analysis.
standard regimen consisting isoniazid (5 mg/kg), rifampin (10 mg/kg), pyrazinamide (25 mg/kg) and ethambutol (15 mg/kg)
standard regimen consisting isoniazid (5 mg/kg), rifampin (10 mg/kg), pyrazinamide (20 mg/kg) and ethambutol (15 mg/kg)
the standard anti-tuberculosis therapy including isoniazid (H), rifampicin (R), pyrazinamide (Z), and thambutol (E)
the standard anti-TB treatment drugs including isoniazid (H), rifampicin (R), pyrazinamide (Z), and thambutol (E)
the first line standard anti-TB treatment drugs including isoniazid, rifampicin, ethambutol and pyrazinamide
experimental group
silymarin, 140 mg, tid
sylibum marianum ( equivalent to 140 mg silymarin), tid
silybum marianum, 200 mg, bid
silibinin, 70 mg, tid
silymarin, 140 mg, bid
control group
placebo, tid
placebo, tid
vitamin C, bid
none
placebo, bid
follow-up
week 2, 4
week 2
week 8
Week2, 4, 8
Week 2, 4, 8
Country
Thailand
Iran
China
China
Korea
Outcomes
①②④
①④
①②③④
①②③④
①②③
Values are presented as number (%) or mean±SD.
①: the occurrence of anti-TB treatment related DILI; ②: liver function tests (ALT, AST, ALP, and TBIL); ③: the occurrence of interruption of anti-TB treatment or taking the second-line TB drugs; ④: adverse events.
All of the studies included in this meta-analysis were described as randomized. In two studies [20, 42], the method of randomization was not clearly described, but randomization was appropriate in other studies [19, 21, 43], which were described as computerized-based. The studies by Gu et al. in 2015 [42] and Zhang et al. in 2016 [21] were open control studies with a high risk of detection and performance bias, while the other three studies [19, 20, 43] used adequate methods to blind the intervention. All of the included studies had a low risk of incomplete outcome data. Selective reporting was low risk in the included studies because the main outcomes stated in the protocol were all reported in the final manuscript. Any other potential biases were unclear in the included studies (Table 2).
Risk of bias assessment in the studies included for meta-analysis.
Study
Random sequence generation (selection bias)
Allocatrion concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data(attrition bias)
Selective reporting (reporting bias)
Other types of bias
Luangchosiri et al. 2015 [19]
L
L
L
L
L
L
U
Marjani et al. 2016 [20]
U
U
L
L
L
L
U
Zhang et al. 2016 [21]
L
H
H
H
L
L
U
Gu et al. 2015 [42]
U
H
H
H
L
L
U
Heo et al. 2017 [43]
L
L
L
L
L
L
U
Criteria defined for quality assessment are based on the Cochrane guidelines.
H: high risk of bias; L: low risk of bias; U: unclear risk of bias.
3.3. The Occurrence of Anti-TB DILI
All the included studies contributed to this analysis and participants were divided into three subgroups with different follow-up periods. Silymarin administration was associated with a significant reduction in the occurrence of anti-TB DILI [RR: 0.33, 95% CI (0.15, 0.75), P = 0.008] with low heterogeneity (P = 0.22, I2 = 33%) at week 4. No significant differences were obtained between the two groups at week 2 (P = 0.64, I2 = 0% ) and week 8 (P = 0.06, I2 = 0%) (Figure 2).
Effect of silymarin on the occurrence of anti-TB DILI with regard to time of follow-up.
3.4. Changes in Liver Enzymes (ALT, AST, ALP, and TBIL)
Three studies [19, 42, 43] reported the effect of silymarin on liver function enzymes. Significant differences were found with respect to change in ALT between silymarin and placebo groups [SMD: − 0.15, 95% CI (−0.24, −0.07), P < 0.001] (Figure 3(a)). In view of different follow-up durations, a subgroup analysis was performed which showed that there was no significant difference in the change in ALT level after 8 weeks of treatment [SMD: − 0.08, 95% CI (−0.23, 0.07), P = 0.30]; however, silymarin significantly decreased ALT levels compared with placebo groups after 2 weeks of treatment [SMD: − 0.16, 95% CI (−0.31, −0.01), P = 0.04] and after 4 weeks of treatment [SMD: − 0.22, 95% CI (−0.37, −0.07), P = 0.003].
Effect of silymarin on changes in the liver function tests. (a) Alanine aminotransferase (ALT). (b) Aspartate aminotransferase (AST).
There was a significant difference between silymarin and placebo groups in terms of AST change [SMD: −0.14, 95% CI (−0.23, −0.06), P = 0.001] (Figure 3(b)). Because of different follow-up durations, we performed a subgroup which showed that there was no significant difference in the change in AST level after 2 weeks of treatment [SMD: − 0.06, 95% CI (−0.22, 0.09), P = 0.40]; however, silymarin noticeably decreased AST levels compared with placebo groups after 4 weeks [SMD: − 0.20, 95% CI (−0.34, −0.05), P = 0.008] and after 8 weeks of treatment [SMD: − 0.16, 95% CI (−0.32, −0.01), P = 0.034].
There was a significant difference between silymarin and placebo groups in terms of ALP change [SMD: −0.12, 95% CI (−0.20, −0.03), P = 0.008] (Figure 4(a)). Because of different follow-up durations, we performed a subgroup analysis which showed that there were no significant differences in the change in ALP level after 2 weeks of treatment [SMD: − 0.08, 95% CI (−0.23, 0.07), P = 0.288] and after 4 weeks of treatment [SMD: − 0.06, 95% CI (−0.21, −0.08), P = 0.40]; however, silymarin noticeably decreased ALP level compared with placebo group after 8 weeks of treatment [SMD: − 0.21, 95% CI (−0.36, −0.06), P = 0.007].
Effect of silymarin on changes in the liver function tests. (a) Alkaline phosphatase (ALP). (b) Total bilirubin (TBIL).
There was no significant difference between silymarin and placebo groups in terms of TBIL change [SMD: −0.03, 95% CI (−0.12, 0.05), P = 0.441] (Figure 4(b)).
3.5. Adverse Event Analysis
Adverse events were reported in four studies [19–21, 42]. Nausea/vomiting was the most frequently reported adverse event [19–21, 42]. Abdominal distension/pain and anorexia were also commonly reported [20, 42]. Rash/exanthema was observed in two studies [20, 21]. Dizziness and pruritus were also observed in two studies [19, 20]. There was no significant difference in the proportion of patients with adverse events in both groups [RR: 1.09, 95% CI (0.86, 1.39), P = 0.47] and with no heterogeneity (P = 0.91, I2 = 0%) (Figure 5).
Effect of silymarin on adverse events in patients undergoing anti-TB treatment.
3.6. Subgroup Analysis
Stratified analysis was also performed based on blinded or open-labelled study designs to explore potential sources of heterogeneity among studies that considered the occurrence of anti-TB DILI as an example. No heterogeneity was found, and the open-labelled study design did not alter the direction of the pooled effect (Supplementary Figure 1(a), Supplementary Figure 1(b)).
3.7. Sensitivity Analysis and Publication Bias
In the sensitivity analysis, we successively eliminated studies one-by-one to recalculate RR, which showed one obvious fluctuation (Supplementary Figure 2(a)). No significant publication bias was detected with Egger’s test (P=0.093). The funnel plot showed symmetry on visual inspection (Supplementary Figure 2(b)).
4. Discussion
Anti-TB DILI is an important and pivotal adverse effect that can occur during the initial two months when combination therapy with three to four anti-TB drugs is required [19]. Any effective measure that can prevent anti-TB DILI is of significance. Therefore, we conducted this meta-analysis to evaluate the effect of silymarin on prevention of anti-TB DILI.
In this meta-analysis, the efficacy of silymarin was assessed by comparing the incidence of anti-TB DILI and changes in the liver enzymes. Fortunately, silymarin reduced the occurrence of anti-TB DILI at week 4 [OR: 0.33, 95% CI (0.15, 0.75), P = 0.008]. Additionally, it reduced ALT levels at weeks 2 and 4, and AST levels at weeks 4 and 8. Moreover, reduction in ALP level at week 8 was significant. However, the effect of silymarin on TBIL level was similar to that of placebo.
A previous study indicated the median interval from treatment initiation of anti-TB drugs to development of clinical symptoms to be 16 weeks (range 6 weeks to 6 months) [44]. According to a recent Korean cohort study focusing on the time of onset of anti-TB DILI that included 1031 TB patients, the majority (67.6%) hepatotoxic events appeared within the first 30 days of anti-TB treatment [45]. This meta-analysis suggested that silymarin showed efficacy in the prevention of anti-TB DILI. Interestingly, silymarin administration significantly reduced the incidence of anti-TB DILI at week 4; however there was no beneficial effect on the incidence at week 8. This showed that silymarin shows hepatoprotective effect during short-term treatment of anti-TB drugs. Previous research studies reported that anti-TB drugs result in oxidative stress, lipid peroxidation, and exhaustion of glutathione reserves [7, 44]. Recent studies supported that INH-induced hepatotoxicity has also been attributed to a reactive metabolite and an immune mediated reaction [6, 46]. These intricate mechanisms responsible for anti-TB DILI may be partly neutralized by the mechanism of hepatoprotection of silymarin. Furthermore, there may be a compensatory or adaptive response against anti-TB DILI, representing immune tolerance that prevents further liver injury, which could interpret delayed onset of DILI [47]. In general, silymarin significantly reduced the incidence of anti-TB DILI at week 4.
Silymarin administration significantly lowers serum AST and ALP levels. Despite silymarin presenting beneficial effects on lowering the serum AST and ALP levels at week 8, it could not reduce the incidence of anti-TB DILI at week 8. This proved that silymarin has no promising hepatoprotective effect in the long-term duration treatment with anti-TB drugs.
Considering the safety of silymarin, only minor adverse effects such as nausea/vomiting, abdominal distension/pain, anorexia, rash/exanthema, and dizziness were reported. All of these reported adverse events were mild and tolerable. Moreover, it showed no significant difference with placebo groups.
There were some limitations to our study. First, the sample size was relatively small with only 585 patients in the silymarin group and 613 in the placebo group. Second, we included two open-labelled studies [21, 42], which may give rise to information bias for the lack of blinding. However, the outcomes were not affected by the absence of blinding. Third, one study [21] chose vitamin C, a potential hepatoprotector [48], as the control instead of a placebo, which may lower the preventive effect of silymarin in anti-TB DILI. In addition, silymarin is a multi-ingredient product, and its effect may vary due to differences in cultivars, active ingredients, and methods of improving low bioavailability [49, 50]. Therefore, further large-scale, well-designed clinical trials are required to confirm and validate the preventive effect of silymarin on anti-TB DILI.
5. Conclusions
Drug-induced liver injury associated with antituberculosis drugs is a common adverse event. It is essential to prevent the occurrence of anti-TB DILI, because anti-TB DILI may affect treatment compliance and therapeutic effectiveness in patients with tuberculosis. This meta-analysis suggested that silymarin showed moderate efficacy in the prevention of anti-TB DILI, as it significantly reduced risk of development of anti-TB DILI at week 4, and decreased serum ALT levels at weeks 2 and 4, serum AST levels at weeks 4 and 8, and ALP level at week 8. In addition, silymarin was well-tolerated. The intricate mechanisms of anti-TB DILI have been poorly understood. Moreover, further studies on the effect of silymarin on the prevention of anti-TB DILI are needed with respect to consensus definition of anti-TB DILI and homogeneous follow-up period.
Conflicts of Interest
The authors declare that they have no conflicts of interest.
Authors’ Contributions
All authors have revised the final manuscript and confirmed that it is never published anywhere.
Acknowledgments
The research was supported by National Natural Science Foundation of China (no. 81803608) and the 8th Youth Foundation of the First Hospital of Jilin University (no. JDYY82017026).
Supplementary Materials
Supplementary Figure 1: subgroup analysis of the occurrence of anti-TB DILI based on blinded or open-labelled study designs. (a) Follow-up at week 4. (b) Follow-up at week 8. Supplementary Figure 2: (a) forest plot of sensitivity analysis in the meta-analysis; (b) funnel plot for the effect of silymarin on the occurrence of anti-TB DILI. Supplementary Table 1: PRISMA 2009 Checklist.
World Health Organization2017World Health OrganizationHorsburghC. R.BarryC. E.LangeC.Treatment of tuberculosis2015373222149216010.1056/nejmra14139192-s2.0-84948412307WuS.XiaY.LvX.TangS.YangZ.ZhangY.WangX.HuD.LiuF.YuanY.TuD.SunF.ZhouL.ZhanS.Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients20153035405452-s2.0-8492322820110.1111/jgh.1271725160904TostmannA.BoereeM. J.AarnoutseR. E.de LangeW. C. M.van der VenA. J. A. M.DekhuijzenR.Antituberculosis drug-induced hepatotoxicity: concise up-to-date review200823219220210.1111/j.1440-1746.2007.05207.x2-s2.0-39149145797SaukkonenJ. J.CohnD. L.JasmerR. M.Hepatotoxicity of antituberculosis therapy2006174893595210.1164/rccm.200510-1666ST2-s2.0-33749856322MetushiI.UetrechtJ.PhillipsE.Mechanism of isoniazid-induced hepatotoxicity: then and now20168161030103610.1111/bcp.12885BaskaranU. L.SabinaE. P.Clinical and experimental research in antituberculosis drug-induced hepatotoxicity: a review2017151273610.1016/S2095-4964(17)60319-4HackettE. S.TwedtD. C.GustafsonD. L.Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease2013271101610.1111/jvim.120022-s2.0-84872407110KiddP. M.Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts20091432262462-s2.0-70350068120LeeJ. I.NarayanM.BarrettJ. S.Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry20078451951032-s2.0-3375154870410.1016/j.jchromb.2006.07.06316942922SherifI. O.Al-GayyarM. M. H.Antioxidant, anti-inflammatory and hepatoprotective effects of silymarin on hepatic dysfunction induced by sodium nitrite20132431141212-s2.0-8488832507710.1684/ecn.2013.0341KarimiG.VahabzadehM.LariP.“Silymarin”, a promising pharmacological agent for treatment of diseases2011144308317AuA. Y.HasenwinkelJ. M.FrondozaC. G.Hepatoprotective effects of S-adenosylmethionine and silybin on canine hepatocytes in vitro20139723313412-s2.0-8487550067210.1111/j.1439-0396.2012.01275.x22320165SinghM.SasiP.GuptaV. H.RaiG.AmarapurkarD. N.WangikarP. P.Protective effect of curcumin, silymarin and201231878879710.1177/0960327111433901EminzadeS.UrazF.IzzettinF. V.Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals200851182-s2.0-48449086178MannA.PelzT.RennertK.MosigA.DeckerM.LuppA.Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance20173042672782-s2.0-8501984021510.1007/s13577-017-0175-9AbenavoliL.CapassoR.MilicN.CapassoF.Milk thistle in liver diseases: past, present, future201024101423143210.1002/ptr.32072-s2.0-77956852506LiuQ.GarnerP.WangY.HuangB.SmithH.Drugs and herbs given to prevent hepatotoxicity of tuberculosis therapy: Systematic review of ingredients and evaluation studies200883653722-s2.0-55149103710LuangchosiriC.ThakkinstianA.ChitphukS.StitchantrakulW.PetraksaS.SobhonslidsukA.A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury20151513342-s2.0-84960403851MarjaniM.BaghaeiP.DizajiM. K.BayaniP. G.FahimiF.TabarsiP.VelayatiA. A.Evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: A randomized clinical trial20161512472522-s2.0-84959345399ZhangS.PanH.PengX.LuH.FanH.ZhengX.XuG.WangM.WangJ.Preventive use of a hepatoprotectant against anti-tuberculosis drug-induced liver injury: A randomized controlled trial201631240941610.1111/jgh.13070KnoblochK.YoonU.VogtP. M.Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias2011392919210.1016/j.jcms.2010.11.0012-s2.0-79952005028HigginsJ.2011The Cochrane Collaborationhttp://handbook.cochrane.org/10.1002/9780470712184WanX.WangW.LiuJ.TongT.Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range20141413510.1186/1471-2288-14-135RamanathanR.SivanesanK.Evaluation of ameliorative ability of Silibinin against zidovudine and isoniazid-induced hepatotoxicity and hyperlipidaemia in rats: Role of Silibinin in Phase I and II drug metabolism20172731421532-s2.0-8502084392510.1016/j.cbi.2017.06.00828619387GhoshK.IndraN.JagadeesanG.The ameliorating effect of Centella asiatica ethanolic extract on albino rats treated with isoniazid201728167772-s2.0-8500847459910.1515/jbcpp-2016-005927701138MartinS. J.SabinaE. P.Amelioration of anti-tuberculosis drug induced oxidative stress in kidneys by Spirulina fusiformis in a rat model2016387111511212-s2.0-8496920431210.1080/0886022X.2016.118494027183989PrinceS. E.UdhayaL. B.SunithaP. S.ArumugamG.Reparation of isoniazid and rifampicin combinatorial therapy-induced hepatotoxic effects by bacopa monnieri2016981-2293410.1159/0004448562-s2.0-84961999238MartinS. J.BaskaranU. L.VediM.SabinaE. P.Attenuation of anti-tuberculosis therapy induced hepatotoxicity by Spirulina fusiformis, a candidate food supplement20142485845922-s2.0-8491004109110.3109/15376516.2014.95691025137345SrivastavaR. K.SharmaS.VermaS.AroraB.LalH.Influence of diabetes on liver injury induced by antitubercular drugs and on silymarin hepatoprotection in rats200830107317372-s2.0-6364910972510.1358/mf.2008.30.10.131682419271021WuJ.-W.TsaiT.-H.Effect of silibinin on the pharmacokinetics of pyrazinamide and pyrazinoic acid in rats2007359160316102-s2.0-3454807878310.1124/dmd.107.01489417540707TasduqS. A.PeerzadaK.KoulS.BhatR.JohriR. K.Biochemical manifestations of anti-tuberculosis drugs induced hepatotoxicity and the effect of silymarin20053131321352-s2.0-1744437169410.1016/j.hepres.2005.01.005OosthuizenC.ArbachM.MeyerD.HamiltonC.LallN.Diallyl Polysulfides from Allium sativum as Immunomodulators, Hepatoprotectors, and Antimycobacterial Agents20172076856902-s2.0-8502375086510.1089/jmf.2016.013728410455CronjéL.EdmondsonN.EisenachK. D.BornmanL.Iron and iron chelating agents modulate Mycobacterium tuberculosis growth and monocyte-macrophage viability and effector functions20054521031122-s2.0-2284444382710.1016/j.femsim.2005.02.00716051061ChanM. K.ChanP. C. K.WongK. K.ChengI. K. P.LiM. K.ChangW. K.Hepatitis B Infection and renal transplantation: the absence of anti-delta antibodies and the possible beneficial effect of silymarin during acute episodes of hepatic dysfunction19894429730110.1093/oxfordjournals.ndt.a0918762-s2.0-0024320768KataokaK.KonoY.SugimotoM.FuruichiY.ShichiriM.TanakaY.Hepatocyte-protective and anti-oxidant effects of rifampicin on human chronic hepatitis C and murine acute hepatocyte disorder201016104110472-s2.0-7804928580310.3892/etm.2010.159ChengS.To research the antiviral treatment of low grade chronic hepatitis B associated with tuberculosis patients (82 cases contrast analysis)Proceedings of the Hepatology international Conference: 26th annual conference of the asian pacific association for the study of the liver, APASL 20172017ChinaBediS.GoelA.ChandN.RaiJ.A prospective study for evaluating the effect of silymarin on hepatic functions in tubercular patients receiving dots2009136474S10.1378/chest.136.4_MeetingAbstracts.74S-a2017https://clinicaltrials.gov/ct2/show/NCT01436929?term=silymarin&cond=tuberculosis&rank=1LiJ.LinW. F.PanY. Y.Protective effect of silibinin on liver injury induced by antituberculosis drugs2010185385386HuZ.YangX.HoP. C. L.SuiY. C.HengP. W. S.ChanE.DuanW.HweeL. K.ZhouS.Herb-drug interactions: a literature review20056591239128210.2165/00003495-200565090-000052-s2.0-22844441147GuJ.TangS. J.TanS. Y.An open-label, randomized and multi-center clinical trial to evaluate the efficacy of Silibinin in preventing drug-induced liver injury20158343204327HeoE.KimD. K.OhS. H.LeeJ.-K.ParkJ.-H.ChungH. S.Effect of prophylactic use of silymarin on anti-tuberculosis drugs induced hepatotoxicity20178032652692-s2.0-8502622217510.4046/trd.2017.80.3.265RamappaV.AithalG. P.Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management201331374910.1016/j.jceh.2012.12.0012-s2.0-84875810348LeeC. M.LeeS. S.LeeJ. M.ChoH. C.KimW. S.KimH. J.HaC. Y.KimH. J.KimT. H.JungW. T.LeeO. J.Early monitoring for detection of antituberculous drug-induced hepatotoxicity201631165722-s2.0-8495451453510.3904/kjim.2016.31.1.6526767859MetushiI. G.ZhuX.ChenX.GardamM. A.UetrechtJ.Mild isoniazid-induced liver injury in humans is associated with an increase in Th17 cells and T cells producing IL-1020142746836892-s2.0-8489941140710.1021/tx500013zMetushiI. G.CaiP.ZhuX.NakagawaT.UetrechtJ. P.A fresh look at the mechanism of isoniazid-induced hepatotoxicity201189691191410.1038/clpt.2010.3552-s2.0-79956313436SuM.ChenH.WeiC.ChenN.WuW.Potential protection of vitamin C against liver-lesioned mice20142224924972-s2.0-8490785188010.1016/j.intimp.2014.07.03425116224AbenavoliL.IzzoA. A.MilićN.CicalaC.SantiniA.CapassoR.Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases201832112202221310.1002/ptr.6171AbouZidS. F.AhmedH. S.Abd El MageedA. M.MoawadA. S.OwisA. I.ChenS.NachtergaelA.McAlpineJ. B.FriesenJ. B.PauliG. F.Linear regression analysis of silychristin A, silybin A and silybin B contents in Silybum marianum20181610.1080/14786419.2018.1527838